Trial Profile
Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms BIC-STaR; BICSTaR
- Sponsors Gilead Sciences
- 05 Apr 2024 Planned End Date changed from 1 Jul 2024 to 1 May 2024.
- 05 Apr 2024 Planned primary completion date changed from 1 Jul 2024 to 1 May 2024.
- 16 Oct 2023 According to a Gilead Sciences media release, data from this study will be presented at 19th European AIDS Conference (EACS) 2023, taking place October 18-21 in Warsaw, Poland.